CorFlow Therapeutics is set to initiate a pivotal trial of its CorFlow CoFl system across US hospitals for heart attack.

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

New 10-year data from the DANAMI-3-PRIMULTI trial show long-term benefits of complete revascularization for patients with STEMI and multivessel disease compared with treatment of the infarct-related ...

Myocardial infarction, commonly known as a heart attack, is one of the most serious heart problems people can face. It ...

When discussing heart health, the words 'myocardial infarction' and 'heart attack' are used interchangeably as if they are ...

Flinders Health and Medical Research Institute researchers, along with colleagues in the UK and U.S., have linked brighter ...

Myocardial infarction (MI) remains the most common cause of death worldwide. Many MI survivors will suffer from recurrent heart failure (HF), which has been recognized as a determinant of adverse ...

Despite the global implementation of clinical algorithms designed to predict atherosclerotic cardiovascular disease based on ...

Individuals with IBD, especially CD, have an increased risk for myocardial infarction, ischemic heart disease, cerebrovascular accident, and major adverse cardiovascular events.

In STEMI-induced cardiogenic shock, a microaxial flow pump can unload the heart by reducing native cardiac output and ...

Lutheran Hospital has been recognized with the 2025 Platinum Performance Achievement Award from the American College of ...